NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue
In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.
The subscription period in the current rights issue in NeuroVive is ongoing until February 6, 2019 and is open to both existing and new investors.
Read more about the rights issue at neurovive.emissioner.se.
Prospectus (in Swedish), containing full terms and conditions, as well as application forms are available on NeuroVive's website www.neurovive.com, Stockholm Corporate Finance AB's website www.stockholmcorp.seand Hagberg & Aneborn Fondkommission AB's website www.hagberganeborn.se.
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 25 January 2019.
For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/
About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).